Allogeneic Hematopoietic Cell Transplantation clinical trials at UCSD
1 research study open to eligible people
Showing trials for
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
open to eligible people ages 18 years and up
This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
La Jolla, California and other locations
Our lead scientists for Allogeneic Hematopoietic Cell Transplantation research studies include Divya Koura, MD.
Last updated: